Search

Displaying results 3081 - 3090 of 7540 in total
  1. Drug

    Theobromine

    go.drugbank.com/drugs/DB01412
    Investigational

    It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension.

  2. Drug

    Levomenol

    go.drugbank.com/drugs/DB13153
    Approved

    . (-)-alpha-Bisabolol is isolated from essential oil of Matricaria chamomilla (German chamomile) (-)-alpha-Bisabolol belongs to the family of Sesquiterpenes.

  3. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  4. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.

  5. Target

    Immunoglobulin heavy variable 3-30

    go.drugbank.com/bio_entities/BE0004312
    TargetHumans

    V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocy...

    Synonyms: Ig heavy chain V-III region BUR
  6. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014. … [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in

  7. Drug

    Indoramin

    go.drugbank.com/drugs/DB08950
    ApprovedWithdrawn

    It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.

  8. Drug

    Clonixin

    go.drugbank.com/drugs/DB09218
    Investigational

    Clonixin is a non-steroidal anti-inflammatory drug.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  9. Drug

    Nicergoline

    go.drugbank.com/drugs/DB00699
    Approved

    It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

  10. Drug

    Flurbiprofen axetil

    go.drugbank.com/drugs/DB14938
    Investigational

    Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal